Subscribe X
Back to Top



July 8, 2013 by Sandra Steingard, MD

A Paradox Revealed – Again

Last week, an important study was published in JAMA Psychiatry. Wunderink and colleagues published results of a follow up study to one he had completed several years ago. In the initial study of first episode psychosis, subjects were randomized to one of two treatment strategies: maintenance treatment (MT) in which they were maintained on drugs for the two year study or drug discontinuation (DR) in which the drugs were stopped and then restarted if symptoms recurred.

Read More

July 2, 2013 by The New York Times | Catherine Rampell

The Half-Trillion-Dollar Depression

2013_Jul2_NYT_JasperRietmanThere are plenty of days when Eliza can’t manage to get herself out of the house. On others, she can’t even get out of bed. And in between, she often can’t sleep, can’t concentrate and can’t remember things. She definitely can’t hold down a job. At least not right now.

Eliza, who asked that I not disclose her last name, successfully battled depression for most of her life. She persevered through college and graduate school and worked steadily for more than a decade as a pharmacist. Then, about two years ago, she suffered from an unusually debilitating stretch in which she didn’t respond to antidepressants, and her insurance company refused to pay for experimental treatments that her doctors recommended. Now in her 40s, she has become one of the more than 1.4 million Americans on the federal disability rolls for mood disorders. She also receives Medicaid, food stamps and fuel assistance. “I never wanted a handout,” Eliza told me last month, adding that she has held on to her pharmacy license in the hope that her condition may yet improve. “I would give anything to get out of this and go back to where I was before.” Read more

Read More

June 27, 2013 by Sandra Steingard, MD

I Am Also Mad

Today I read Psychiatric News, the newspaper of the American Psychiatric Association, and I was drawn to an article about the new APA President, Jeffrey Lieberman, because the front page teaser announced that “he is ‘mad as hell’”.What, I wondered, is he so mad about?

In the article, which reports on Dr. Lieberman’s address at the opening session of the annual APA meeting in May, we learn that he is angry not only about “stigma associated with mental illness” but also “the lack of respect toward psychiatry as a medical specialty”.

Read More

June 11, 2013 by Bob Nikkel, MSW

Canadian Provider Association Publishes Guide to Reducing Antipsychotic Use

An interesting thing has been happening in Canada. In late 2011, the British Columbia Ministry of Health issued a report entitled, “A Review of the Use of Antipsychotic Drugs in British Columbia Residential Care Facilities.” The family of a senior living in such a facility raised the issue of over-medication and, instead of reacting defensively, the provincial government set about studying the prescribing practices of physicians in these residential programs.

Read More

June 3, 2013 by Sandra Steingard, MD

Failures of the Medical Model

Recently I had dinner with several primary care physicians who had just read Anatomy of an Epidemic. They had heard of my interest in this book and they asked to discuss it with me.These are physicians I have known for many years and in my opinion they reflect everything that is good in medicine. They are dedicated, caring, and humanistic. But the conversation reflected for me everything that is wrong with the modern practice of medicine. Although there are the ways in which psychiatry is different from the rest of medicine, there are ways in which it is similar and I am not sure we can expect much to change if we do not address some of these similarities.

Read More

April 23, 2013 by Bob Nikkel, MSW

The Words We Use…

David Romprey walked up to me one day when I was in the middle of planning the next new 16-bed facility in a community setting for people who were in our state hospitals in Oregon. Progress was in the making.He asked why I called these places 16-“bed” facilities. Answering matter-of-factly what seemed obvious, I replied that these residences, nicely furnished in pleasant neighborhoods, had 16 beds. Looking me straight in the eye, as he always did, David asked me, “Do you think we’re lying around prostrate all the time?”

Read More

April 22, 2013 by Sandra Steingard, MD

All Sorts of Realities

In previous posts in this series, I noted that the standard treatment of conditions labeled as schizophrenia (and related disorders) is to start neuroleptics early and to continue them indefinitely. This is based on the belief that untreated psychosis is bad for the brain and that relapse is much higher when the drugs are stopped than when they are continued. The rationale for this approach, and my discussion of the limitations of these assertions, were the topics of previous blogs in this series.

Read More

April 14, 2013 by Sandra Steingard, MD

Optimal Use of Neuroleptics, Part 3: Duration of Untreated Psychosis

For the past 20 years, there has been a prevailing concern in psychiatry that psychosis is bad for the brain. The notion is that the psychotic process is in and of itself damaging and therefore every effort should be made to curtail this process in order to forestall further damage. This idea heightened the urgency to initiate drug treatment. When I read Anatomy of an Epidemic, this was one of my most pressing concerns; If I suggested to my patients that they pursue other treatments before starting drug treatment, was I helping or harming them?

Read More

March 31, 2013 by Sandra Steingard, MD

Optimal Use of Neuroleptic Drugs, Pt. II: The Monkeys Were Not Psychotic

I asserted previously that the impression of short term efficacy tends to be inflated. What I mean by this is that there is a general sense – within my profession and among the general public – that neuroleptic drugs are very effective. They are after all what allowed us to shutter our state hospitals. The folk narrative is that the main problem is not that they do not work but that people do not take them reliably so we should therefore put our efforts into getting people to stay on them.

Read More

March 25, 2013 by Sandra Steingard, MD

Optimal Use of Neuroleptic Drugs: An Introduction

I have recently put together a talk in which I summarize my current thinking on the optimal use of neuroleptic drugs, primarily focusing on the treatment of individuals who are experiencing psychotic symptoms. In order to foster conversation on this topic, I will be posting the content of this talk in a series of blogs.

Read More

Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
  • 1boringoldman


    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.